ASO作者反思：NEO-GAP：一项新辅助吉西他滨、顺铂和纳米白蛋白结合型紫杉醇用于可切除的高危肝内胆管癌的单臂II期可行性试验。 - Suppr

Suppr

超能文献

ASO Author Reflections: NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma.

作者信息

Maithel Shishir K

机构信息

Division of Surgical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA.

出版信息

Ann Surg Oncol. 2023 Oct;30(11):6567-6568. doi: 10.1245/s10434-023-13811-x. Epub 2023 Jun 29.

DOI:10.1245/s10434-023-13811-x

PMID:37386309

Abstract

摘要

相似文献

ASO Author Reflections: NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma.ASO作者反思：NEO-GAP：一项新辅助吉西他滨、顺铂和纳米白蛋白结合型紫杉醇用于可切除的高危肝内胆管癌的单臂II期可行性试验。

Ann Surg Oncol. 2023 Oct;30(11):6567-6568. doi: 10.1245/s10434-023-13811-x. Epub 2023 Jun 29.

NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma.NEO-GAP：吉西他滨、顺铂和 Nab-紫杉醇新辅助治疗可切除高危肝内胆管细胞癌的单臂、II 期可行性试验。

Ann Surg Oncol. 2023 Oct;30(11):6558-6566. doi: 10.1245/s10434-023-13809-5. Epub 2023 Jun 27.

Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.新辅助治疗加辅助治疗或仅辅助纳武利尤单抗联合吉西他滨治疗可切除胰腺癌- NEONAX 试验（AIO-PAK-0313），AIO 胰腺癌组的一项前瞻性、随机、对照、II 期研究。

BMC Cancer. 2018 Dec 29;18(1):1298. doi: 10.1186/s12885-018-5183-y.

Clinical feasibility of curative surgery after nab-paclitaxel plus gemcitabine-cisplatin chemotherapy in patients with locally advanced cholangiocarcinoma.白蛋白结合型紫杉醇联合吉西他滨-顺铂化疗后局部晚期胆管癌患者进行根治性手术的临床可行性

Surgery. 2023 Feb;173(2):280-288. doi: 10.1016/j.surg.2022.09.028. Epub 2022 Nov 23.

A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.nab-紫杉醇联合吉西他滨加或不加卡培他滨和顺铂治疗局部晚期或可切除边界胰腺癌的随机 2 期临床试验。

Eur J Cancer. 2018 Oct;102:95-102. doi: 10.1016/j.ejca.2018.07.007. Epub 2018 Aug 24.

ASO Author Reflections: Impact of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer on Surgical Outcomes.ASO作者反思：吉西他滨联合白蛋白结合型紫杉醇新辅助化疗对可切除边缘性胰腺癌手术结局的影响

Ann Surg Oncol. 2019 Dec;26(Suppl 3):739-740. doi: 10.1245/s10434-019-07857-z. Epub 2019 Sep 19.

Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group.围手术期或仅辅助使用吉西他滨联合白蛋白结合型紫杉醇治疗可切除胰腺癌（NEONAX）——AIO胰腺癌组的一项随机II期试验

Ann Oncol. 2023 Jan;34(1):91-100. doi: 10.1016/j.annonc.2022.09.161. Epub 2022 Oct 7.

ASO Author Reflections: Neoadjuvant Treatment of Resectable and Borderline-Resectable Pancreatic Head Adenocarcinoma: Is FOLFIRINOX Better than Gem/Nab-Paclitaxel?ASO作者反思：可切除及边界可切除胰头腺癌的新辅助治疗：FOLFIRINOX方案是否优于吉西他滨/纳米白蛋白结合型紫杉醇？

Ann Surg Oncol. 2018 Dec;25(Suppl 3):808-809. doi: 10.1245/s10434-018-6833-7. Epub 2018 Oct 8.

A Phase II Study of Nab-Paclitaxel and Gemcitabine as First-Line Therapy in Patients with Cholangiocarcinoma Ineligible for Cisplatin-Based Chemotherapy (NACHO).一项关于纳米白蛋白结合型紫杉醇与吉西他滨作为无法接受基于顺铂化疗的胆管癌患者一线治疗方案的II期研究（NACHO）。

Oncol Res Treat. 2023;46(3):89-99. doi: 10.1159/000529012. Epub 2023 Jan 9.

Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparative multicenter phase II trial.术前使用 mFOLFIRINOX 或吉西他滨/ Nab-紫杉醇 +/- 等毒量立体定向体部放射治疗（iHD-SBRT）治疗边界可切除胰腺腺癌（STEREOPAC 试验）：一项随机比较多中心 II 期试验的研究方案。

BMC Cancer. 2023 Sep 21;23(1):891. doi: 10.1186/s12885-023-11327-x.

本文引用的文献

Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study.吉西他滨和顺铂联合度伐利尤单抗（无论是否联合曲美木单抗）用于既往未接受过化疗的晚期胆管癌患者：一项开放标签、单中心、2期研究。

Lancet Gastroenterol Hepatol. 2022 Jun;7(6):522-532. doi: 10.1016/S2468-1253(22)00043-7. Epub 2022 Mar 9.

Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial.吉西他滨、顺铂和 nab-紫杉醇治疗晚期胆道癌：一项 2 期临床试验。

JAMA Oncol. 2019 Jun 1;5(6):824-830. doi: 10.1001/jamaoncol.2019.0270.

Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.卡培他滨对比观察用于可切除胆管癌（BILCAP）：一项随机、对照、多中心、3 期研究。

Lancet Oncol. 2019 May;20(5):663-673. doi: 10.1016/S1470-2045(18)30915-X. Epub 2019 Mar 25.

Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline.胆道癌切除术后辅助治疗：ASCO 临床实践指南。

J Clin Oncol. 2019 Apr 20;37(12):1015-1027. doi: 10.1200/JCO.18.02178. Epub 2019 Mar 11.

Cholangiocarcinoma - evolving concepts and therapeutic strategies.胆管癌——不断演变的概念与治疗策略

Nat Rev Clin Oncol. 2018 Feb;15(2):95-111. doi: 10.1038/nrclinonc.2017.157. Epub 2017 Oct 10.

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.顺铂联合吉西他滨与吉西他滨治疗胆管癌。

N Engl J Med. 2010 Apr 8;362(14):1273-81. doi: 10.1056/NEJMoa0908721.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验